


アキシチニブ

Axitinib

アキシチニブは、根治切除不能または転移性の腎細胞癌に効能があると知られています。CAPCELL CORE C₁₈ S2.7 (2.1 mm i.d. x 100 mm) を用いた例では約 12 分に良好なピーク形状にて溶出しました。

Axitinib is known to show efficacy towards unresectable or metastatic renal cell carcinoma. The compound was eluted as an efficient peak with CAPCELL CORE C₁₈ S2.7 (2.1 mm i.d. x 100 mm).



【HPLC Conditions】

Column	: CAPCELL CORE C ₁₈ S2.7 ; 2.1 mm i.d. x 100 mm
Mobile phase	: 0.1 vol% H ₃ PO ₄ / CH ₃ CN= 85 / 15
Flow rate	: 200 µL/min
Temperature	: 40 °C
Detection	: PDA 360 nm
Inj. vol.	: 1 µL
Sample dissolved in	: Standard compound was dissolved in CH ₃ OH at 1000 µg/mL, and then, diluted with the mobile phase. (0.5 µg/mL as Axitinib)